“一带一路”战略框架下的埃博拉病毒病防控战役

新发传染病电子杂志 ›› 2019, Vol. 4 ›› Issue (4): 200-203.

• 卫生健康事业发展70年巡礼--重大传染病防治 • 上一篇下一篇

“一带一路”战略框架下的埃博拉病毒病防控战役

卢洪洲^{1, 3, 4}, 袁伟^2#

1.复旦大学附属上海市公共卫生临床中心感染与免疫科, 上海 201805;
2.复旦大学附属上海市公共卫生临床中心重症肝病科, 上海 201805；
3.复旦大学附属华山医院感染科, 上海 200040；
4.复旦大学上海医学院内科学系, 上海 200032

出版日期:2019-12-30 发布日期:2020-07-21
通讯作者: 卢洪洲, Email:luhongzhou@fudan.edu.cn

Strategies of prevention and control for Ebola virus under the frame of "One Beld and One Road"

LU Hong-zhou^{1, 3, 4}, YUAN Wei²

1. Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China;
2. Department of Severe Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China;
3. Huashan Hospital, Fudan University, Shanghai, 200040, China;
4.Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, 200032, China

Online:2019-12-30 Published:2020-07-21

摘要/Abstract

摘要： 由于埃博拉病毒病具有较高的病死率, 其历次暴发流行对国际公共卫生安全带来了不小的隐患。在“一带一路”战略框架下, 我国不仅在国内建立了从临床救治到联防联控的系统性应急响应机制, 也对西非疫情较重的国家进行了援助。在国际社会的关注和国家卫生系统的主动作为下, 随着新药物和疫苗的诞生, 必定能战胜埃博拉病毒。

关键词: 埃博拉病毒病, 疾病防控, 一带一路

Abstract: Ebola virus disease is thought to be a great threat to international public health security due to its high mortality. Under the frame of “One Belt and One Road”initiation, we have established a series of response mechanism to ensure the safety of public health at home and abroad. With the increasing exploitation of new medicaments and vaccines, the epidemic of ebola virus is bound to end.

Key words: Ebola virus diseases, Disease prevention and control, One Beld and One Road

卢洪洲, 袁伟. “一带一路”战略框架下的埃博拉病毒病防控战役[J]. 新发传染病电子杂志, 2019, 4(4): 200-203.

LU Hong-zhou, YUAN Wei. Strategies of prevention and control for Ebola virus under the frame of "One Beld and One Road"[J]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(4): 200-203.

参考文献

[1] WHO.Fact sheet on Ebola virus disease[EB/OL].https://www.who.int/csr/resources/publications/ebola/coordination/en.
[2] WHO. Introduction to Ebola virus disease [EB/OL].https://www.who.int/csr/resources/publications/presentation.pdf?ua=1&ua=1.
[3] Coltart CE, Lindsey B, Ghinai I, et al.The ebola outbreak, 2013-2016: old lessons for new epidemics[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1721): 20160297.
[4] WHO. 2016 Ebola situation reports: archive [EB/OL]. http://www.who.int/csr/disease/ebola/situation-reports/archive/en.
[5] WHO. Ebola virus diseases [EB/OL].https://www.who.int/health-topics/ebola/#tab=overview.
[6] Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease): Transmission [EB/OL].https://www.cdc.gov/vhf/ebola/transmission/index.html.
[7] Harbourt DE, Johnston SC, Pettitt J, et al.Detection of Ebola Virus RNA Through Aerosol Sampling of Animal Biosafety Level 4 Rooms Housing Challenged Nonhuman Primates[J]. J Infect Dis, 2017, 215(4): 554-558.
[8] Mekibib B, Ariën KK.Aerosol Transmission of Filoviruses[J]. Viruses, 2016, 8(5): 148.
[9] Olejnik J, Ryabchikova E, Corley RB, et al.Intracellular events and cell fate in filovirus infection[J]. Viruses, 2011, 3(12): 1501-1531.
[10] WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections[J]. N Engl J Med, 2014, 371(16): 1481-1495.
[11] Warren TK, Wells J, Panchal RG, et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430[J]. Nature, 2014, 508(7496): 402-405.
[12] Florescu DF, Keck MA.Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses[J]. Expert Rev Anti Infect Ther, 2014, 12(10): 1171-1178.
[13] Smither SJ, Eastaugh LS, Steward JA, et al.Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model[J]. Antiviral Res, 2014, 104(3): 153-155.
[14] Wu W, Liu S.The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection[J]. Curr Top Med Chem, 2017, 17(3):361-370.
[15] Qiu X, Wong G, Audet J, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp[J]. Nature, 2014, 514(7520): 47-53.
[16] 冯子健. 埃博拉出血热及其防控策略(视频)[J]. 新发传染病电子杂志, 2017, 2(1):59.
[17] WHO. Travel and transport risk assessment: Ebola [EB/OL].https://apps.who.int/iris/bitstream/handle/10665/132168/WHO_EVD_Guidance_TravelTransportRisk_14.1_eng.pdf?sequence=1.
[18] WHO. Ebola event management at points of entry [EB/OL].https://apps.who.int/iris/bitstream/handle/10665/131827/WHO_EVD_Guidance_PoE_14.1_eng.pdf?sequence=1.
[19] WHO. Ebola in the Democratic Republic of the Congo: health emergency update [EB/OL]. Available from: https://www.who.int/emergencies/diseases/ebola/drc-2019.
[20] Kennedy SB, Bolay F, Kieh M, et al.Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia[J]. N Engl J Med, 2017, 377(15): 1438-1447.
[21] Henao-Restrepo AM1, Longini IM2, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial[J]. Lancet, 2015, 386(9996): 857-866.
[22] Milligan ID, Gibani MM, Sewell R, et al.Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial[J]. JAMA, 2016, 315(15): 1610-1623.
[23] Bengtsson KL, Song H, Stertman L, et al.Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice[J]. Vaccine, 2016, 34(16): 1927-1935.

“一带一路”战略框架下的埃博拉病毒病防控战役

Strategies of prevention and control for Ebola virus under the frame of "One Beld and One Road"

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价